CO2022004686A2 - Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo - Google Patents
Compuesto de piridona fusionada y método de preparación del mismo y uso del mismoInfo
- Publication number
- CO2022004686A2 CO2022004686A2 CONC2022/0004686A CO2022004686A CO2022004686A2 CO 2022004686 A2 CO2022004686 A2 CO 2022004686A2 CO 2022004686 A CO2022004686 A CO 2022004686A CO 2022004686 A2 CO2022004686 A2 CO 2022004686A2
- Authority
- CO
- Colombia
- Prior art keywords
- preparation
- compound
- pyridone compound
- fused
- fused pyridone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910892032 | 2019-09-20 | ||
| CN201911129688 | 2019-11-18 | ||
| CN201911157939 | 2019-11-22 | ||
| CN202010054188 | 2020-01-17 | ||
| CN202010102546 | 2020-02-19 | ||
| CN202010230303 | 2020-03-27 | ||
| CN202010306926 | 2020-04-17 | ||
| CN202010367694 | 2020-04-30 | ||
| CN202010967317 | 2020-09-15 | ||
| PCT/CN2020/116510 WO2021052499A1 (zh) | 2019-09-20 | 2020-09-21 | 稠合吡啶酮类化合物及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2022004686A2 true CO2022004686A2 (es) | 2022-07-08 |
Family
ID=74883935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2022/0004686A CO2022004686A2 (es) | 2019-09-20 | 2022-04-12 | Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo |
Country Status (15)
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| ES3065954T3 (en) | 2019-05-13 | 2026-05-08 | Relay Therapeutics Inc | Fgfr inhibitors and methods of use thereof |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| BR112022008375A2 (pt) * | 2019-10-30 | 2022-07-12 | Genfleet Therapeutics Shanghai Inc | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| MX2022005359A (es) | 2019-11-04 | 2022-06-02 | Revolution Medicines Inc | Inhibidores de ras. |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| AU2021248363B2 (en) * | 2020-04-03 | 2024-02-15 | Medshine Discovery Inc. | Octahydropyrazinodiazanaphthyridine dione compounds |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| CN116406363B (zh) * | 2020-08-21 | 2025-06-20 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法及其医药上的用途 |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as RAS inhibitors in cancer therapy |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| TWI924727B (zh) | 2020-11-18 | 2026-05-11 | 美商傳達治療有限公司 | Ｆｇｆｒ抑制劑及其製造及使用方法 |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| CN116670136A (zh) * | 2020-12-31 | 2023-08-29 | 正大天晴药业集团股份有限公司 | 四环类化合物及其医药用途 |
| CN116964056B (zh) * | 2021-03-25 | 2026-04-10 | 上海济煜医药科技股份有限公司 | 稠合吡啶酮类化合物盐型、晶型及其应用 |
| CN115124533A (zh) * | 2021-03-26 | 2022-09-30 | 浙江海正药业股份有限公司 | 四环类衍生物、其制备方法和其医药上的用途 |
| WO2022198904A1 (zh) * | 2021-03-26 | 2022-09-29 | 浙江海正药业股份有限公司 | 一种kras抑制剂关键中间体及其制备方法 |
| WO2022206723A1 (zh) * | 2021-03-30 | 2022-10-06 | 浙江海正药业股份有限公司 | 杂环类衍生物、其制备方法及其医药上的用途 |
| WO2022223037A1 (zh) * | 2021-04-22 | 2022-10-27 | 劲方医药科技(上海)有限公司 | Kras抑制剂的盐或多晶型物 |
| CA3226720A1 (en) * | 2021-07-23 | 2023-01-26 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| CN117222654A (zh) * | 2021-09-06 | 2023-12-12 | 苏州赞荣医药科技有限公司 | Kras g12c抑制剂和其用途 |
| WO2023116895A1 (zh) * | 2021-12-24 | 2023-06-29 | 劲方医药科技(上海)有限公司 | Kras抑制剂的多晶型物及其制备方法和用途 |
| CN116327956B (zh) * | 2022-04-01 | 2025-11-28 | 劲方医药科技(上海)股份有限公司 | 药物组合物、其用途及癌症的治疗方法 |
| CN119998295A (zh) | 2022-06-08 | 2025-05-13 | 因赛特公司 | 作为dgk抑制剂的三环三唑并化合物 |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US20260137665A1 (en) | 2022-10-11 | 2026-05-21 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN121013721A (zh) * | 2022-11-23 | 2025-11-25 | 沪亚生物国际有限公司 | 包含kras抑制剂和sph2抑制剂的组合疗法 |
| WO2025016436A1 (zh) * | 2023-07-19 | 2025-01-23 | 上海济煜医药科技有限公司 | Kras抑制剂的制备方法、其中间体和其中间体的制备方法 |
| WO2025036442A1 (zh) * | 2023-08-15 | 2025-02-20 | 劲方医药科技(上海)股份有限公司 | 吡嗪并萘啶二酮类化合物的制备方法及其中间体 |
| KR20260104082A (ko) | 2023-09-29 | 2026-07-03 | 디3 바이오 (우씨) 컴퍼니, 리미티드 | 암의 치료에 사용하기 위한 wx-001 또는 그의 유도체와 kras g12c 억제제의 조합물 |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| WO2025256521A1 (zh) * | 2024-06-11 | 2025-12-18 | 上海济煜医药科技有限公司 | 作为kras抑制剂的稠合吡啶酮类化合物的制备方法、中间体及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX380928B (es) | 2013-10-10 | 2025-03-12 | Araxes Pharma Llc | Inhibidores de kras g12c. |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| AU2016245864C1 (en) * | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| ES2856880T3 (es) * | 2015-04-15 | 2021-09-28 | Araxes Pharma Llc | Inhibidores tricíclicos condensados de KRAS y métodos de uso de los mismos |
| RU2722149C1 (ru) * | 2015-09-14 | 2020-05-27 | Пфайзер Инк. | Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2 |
| KR102932353B1 (ko) | 2015-11-16 | 2026-02-27 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) * | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2018142365A1 (en) * | 2017-02-03 | 2018-08-09 | The University Of North Carolina At Chapel Hill | Inhibitors of microbial beta-glucuronidase enzymes and uses thereof |
| WO2018206539A1 (en) * | 2017-05-11 | 2018-11-15 | Astrazeneca Ab | Heteroaryl compounds that inhibit g12c mutant ras proteins |
| UA127968C2 (uk) * | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10597405B2 (en) * | 2017-12-08 | 2020-03-24 | Astrazeneca Ab | Chemical compounds |
| SG10202102462SA (en) * | 2018-01-19 | 2021-04-29 | Medshine Discovery Inc | Pyridone-pyrimidine derivative acting as krasg12c mutein inhibitor |
| MX2020010836A (es) * | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| CN111484477B (zh) * | 2019-01-29 | 2022-07-08 | 博瑞生物医药（苏州）股份有限公司 | 一种苯并吡啶酮杂环化合物及其用途 |
| CN113396147B (zh) * | 2019-05-31 | 2024-06-18 | 上海翰森生物医药科技有限公司 | 芳香杂环类衍生物调节剂、其制备方法和应用 |
| CN112300194B (zh) * | 2019-07-30 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类稠环吡啶酮类化合物、制备方法和用途 |
| BR112022008375A2 (pt) * | 2019-10-30 | 2022-07-12 | Genfleet Therapeutics Shanghai Inc | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste |
-
2020
- 2020-09-21 CN CN202310905052.2A patent/CN116947885B/zh active Active
- 2020-09-21 JP JP2022517446A patent/JP7642619B2/ja active Active
- 2020-09-21 EP EP20865331.1A patent/EP4043464A4/en active Pending
- 2020-09-21 WO PCT/CN2020/116510 patent/WO2021052499A1/zh not_active Ceased
- 2020-09-21 MX MX2022003401A patent/MX2022003401A/es unknown
- 2020-09-21 AU AU2020350745A patent/AU2020350745B2/en active Active
- 2020-09-21 KR KR1020227013103A patent/KR102984049B1/ko active Active
- 2020-09-21 PH PH1/2022/550681A patent/PH12022550681A1/en unknown
- 2020-09-21 CN CN202410656034.XA patent/CN118619971A/zh active Pending
- 2020-09-21 TW TW109132517A patent/TWI761961B/zh active
- 2020-09-21 CN CN202411842480.6A patent/CN119462689A/zh active Pending
- 2020-09-21 BR BR112022005193A patent/BR112022005193A2/pt unknown
- 2020-09-21 US US17/761,983 patent/US20220389029A1/en active Pending
- 2020-09-21 CN CN202080078771.6A patent/CN114728968B/zh active Active
- 2020-09-21 CA CA3155066A patent/CA3155066A1/en active Pending
- 2020-09-21 CN CN202411842482.5A patent/CN119591618A/zh active Pending
-
2022
- 2022-03-17 IL IL291467A patent/IL291467B2/en unknown
- 2022-03-18 CL CL2022000666A patent/CL2022000666A1/es unknown
- 2022-04-12 CO CONC2022/0004686A patent/CO2022004686A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116947885A (zh) | 2023-10-27 |
| CN114728968B (zh) | 2024-11-15 |
| KR20220086573A (ko) | 2022-06-23 |
| US20220389029A1 (en) | 2022-12-08 |
| TW202126654A (zh) | 2021-07-16 |
| IL291467B1 (en) | 2026-03-01 |
| IL291467B2 (en) | 2026-07-01 |
| KR102984049B1 (ko) | 2026-06-29 |
| JP2022549171A (ja) | 2022-11-24 |
| JP7642619B2 (ja) | 2025-03-10 |
| EP4043464A1 (en) | 2022-08-17 |
| PH12022550681A1 (en) | 2023-04-24 |
| CN116947885B (zh) | 2026-01-23 |
| BR112022005193A2 (pt) | 2022-08-16 |
| IL291467A (en) | 2022-05-01 |
| MX2022003401A (es) | 2022-07-13 |
| AU2020350745B2 (en) | 2026-03-26 |
| AU2020350745A1 (en) | 2022-04-07 |
| CN119591618A (zh) | 2025-03-11 |
| CN118619971A (zh) | 2024-09-10 |
| CA3155066A1 (en) | 2021-03-25 |
| EP4043464A4 (en) | 2023-10-04 |
| CN114728968A (zh) | 2022-07-08 |
| WO2021052499A1 (zh) | 2021-03-25 |
| TWI761961B (zh) | 2022-04-21 |
| CL2022000666A1 (es) | 2022-10-14 |
| CN119462689A (zh) | 2025-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022000666A1 (es) | Compuesto de piridona fusionada y método de preparación del mismo y uso del mismo | |
| MX2022001421A (es) | Compuesto tetracíclico, método de preparación y uso del mismo. | |
| ECSP22057865A (es) | Inhibidores de formas mutantes de egfr | |
| ECSP17054980A (es) | Inhibidores selectivos de bace1 | |
| CL2019003086A1 (es) | Compuestos de imidazo-piperidina fusionada como inhibidores de jak. | |
| CO2019005165A2 (es) | Compuesto de piridona como inhibidor de c-met | |
| CY1124855T1 (el) | 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2019001581A (es) | Inhibidores de ssao de aminopirimidina. | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| UY35362A (es) | Compuestos terapéuticos | |
| CL2019001694A1 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos. | |
| MX2018000280A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2018013191A (es) | Compuestos de pirimidina como inhibidores de la quinasa jak. | |
| CR20170003A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CO2020012574A2 (es) | Método para la preparación de una 1,2,4-triazolona 2,4,5-trisustituida | |
| BR112021026556A2 (pt) | Composto tricíclico, método de preparação para ele e uso dele | |
| CO2021004873A2 (es) | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa | |
| EA201792320A1 (ru) | Способ лечения рака ингибитором пути stat3 и ингибитором киназы | |
| ECSP19013196A (es) | Derivado de triazolopirazinona útil como un inhibidor de pde1 humana | |
| EA202191192A1 (ru) | Кристаллические соли ингибитора плазменного калликреина | |
| AR099766A1 (es) | Inhibidores de la quinasa asociada al adaptador 1, composiciones que los comprenden y métodos para utilizarlos | |
| MX2021002503A (es) | Métodos de tratamiento de infecciones micobacterianas usando compuestos de tetraciclina. | |
| MX2022006984A (es) | Procesos e intermediario para la preparacion de oxetan-2-ilmetanamina. | |
| AR106475A1 (es) | Derivados de piridina o de pirimidina |